QS Investors’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

QS Investors’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$331K	Hold	2,048	–	–	﹤0.01%	910
2021 Q1	$351K	Sell	2,048 -1,175	-36%	-$233K	﹤0.01%	925
2020 Q4	$708K	Sell	3,223 -52	-2%	-$11.2K	0.01%	622
2020 Q3	$544K	Buy	3,275 +3,175	+3,175%	+$434K	0.01%	650
2020 Q2	$12K	Buy	+100	New	+$9.7K	﹤0.01%	1527
2020 Q1	–	Sell	-1,300	Closed	-$152K	–	1711
2019 Q4	$152K	Hold	1,300	–	–	﹤0.01%	1256
2019 Q3	$102K	Buy	+1,300	New	+$122K	﹤0.01%	1385

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

QS Investors's MRTX Position: Q2 2021 in Review

QS Investors held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q2 2021 at 2,048 shares worth $331K. The position accounts for ﹤0.01% of the portfolio, ranked #910.

QS Investors first reported a position in MRTX in Q3 2019 and has held it in 7 quarters since. The position peaked at $708K in Q4 2020. 245 funds tracked by Wall St. Rank hold MRTX as of Q2 2021.

QS Investors held 2,048 shares of Mirati Therapeutics, Inc. Common Stock worth $331K as of Q2 2021.
QS Investors left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q2 2021.
Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #910 holding.
QS Investors first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2019 and has held it in 7 quarters since.
QS Investors's Mirati Therapeutics, Inc. Common Stock position peaked at $708K in Q4 2020.
245 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.